You are currently viewing Entyvio


What is Entyvio?

Entyvio is a medication that reduces inflammation caused by a substance in the body. It is used to treat moderate to severe ulcerative colitis or Crohn’s disease in adults. Entyvio can reduce the symptoms of these diseases and help maintain control long-term. It can also reduce the need for steroid medicines to control symptoms. Entyvio is typically given after other treatments have failed.

However, there are several warnings associated with the use of Entyvio. It can cause serious side effects on the brain or liver and may lead to a severe infection. If you experience fever, tiredness, muscle aches, sore throat, shortness of breath, skin sores, painful urination, loss of appetite, upper stomach pain, dark urine, yellowing of your skin and eyes, or problems with speech, thought, vision, or muscle movement, contact your doctor immediately. You should also inform your healthcare provider of any reactions you experience during the injection, such as dizziness, nausea, itching, headache, chest tightness, trouble breathing, or swelling in your face.

Additionally, you should not receive a “live” vaccine while using Entyvio. If you are allergic to vedolizumab, do not use Entyvio. It is crucial to tell your doctor if you have any infections or signs of infection, liver disease, scheduled vaccines, tuberculosis, or recent travel. Make sure you are up to date with all the required vaccinations before using Entyvio.

Entyvio is administered through an infusion into a vein by a healthcare provider, usually every 2 to 8 weeks. The provider will monitor you closely for a short time after the infusion to ensure that you do not have an allergic reaction. It may take several weeks before you notice any improvements in your symptoms. Keep using the medication as directed and let your doctor know if your symptoms do not improve after 14 weeks of treatment.

The usual adult dose for Crohn’s disease and ulcerative colitis is 300 mg IV over 30 minutes at Week 0, 2, and 6 and then every 8 weeks thereafter. Patients should be up to date with all immunizations before starting therapy, and Entyvio should be discontinued if there is no evidence of therapeutic benefit by Week 14.

In summary, while Entyvio can help reduce the symptoms of ulcerative colitis or Crohn’s disease, it is crucial to be aware of the potential side effects and warnings associated with its use. Be sure to inform your doctor of any pre-existing conditions or medications you are taking before beginning treatment.

Leave a Reply